Tecan Group AG

Tecan Group AG Achieves Mid-Single-Digit Revenue Growth in Q3 2025, Maintains Full-Year Outlook

Tecan Group AG reported mid-single-digit revenue growth in Q3 2025, reaffirming its full-year 2025 outlook despite segment-level variations.

Tecan Group AG
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

13/10/2025, 06:40

2 minutes to read

Tecan Group AG Reports Mixed Financial Results Amid Market Volatility

Tecan Group AG reported a mixed financial performance for the first half of 2025, with a 3.7% sales decline, but remains optimistic about its future in the Life Sciences sector.

Tecan Group AG
Health Care
Pharmaceuticals, Biotechnology & Life Sciences
AI generated

12/08/2025, 12:29

3 minutes to read